Floatz logo

Mesothelin-Directed Car-T Cells

Pancreatic Cancer Non-resectable

Essen BiotechCell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Pancreatic Cancer Non-resectable cohort.

Asset / SponsorPhaseRating
Tunlametinib
Chinese PLA General Hospital
Phase 4BB
Cetuximab
Chinese PLA General Hospital
Phase 4BB
Huaier Granule
Xi'an Jiaotong University
Phase 4BB
IMMUNOGLOBULIN G1, ANTI-(HUMANIZED MOUSE MONOCLONAL HR3 .BETA.1 CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL HR3 .KAPPA.-CHAIN, DIMER
Peking University First Hospital
Phase 2CCC
Zanubrutinib
Shandong Cancer Hospital and Institute
Phase 2CCC

View all 9 →

Same molecule, other indications

Mesothelin-Directed Car-T Cells is also rated in:

Pancreatic CarcinomaDormant
CC
Indicative ·
45 / 100
View asset →
Pancreatic CancerDormant
CC
Indicative ·
40 / 100
View asset →
Solid Tumor, AdultDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →